The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune ‐Mediated Inflammatory Disease

ConclusionsWith the exception of female sex in RA, axSpA, and CD, none of the candidate predictors were associated with SB5 discontinuation. Persistence on SB5 was high, treatment effectiveness was maintained, and no safety signals were detected.Trial RegistrationThis trial is registered with ClinicalTrials.gov: NCT04089514.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research